FDA Approval Validates MAIA Biotechnology’s Telomere-Targeting Therapy Using a Telomerase Inhibitor

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage enterprise dedicated to developing telomere-targeting immunotherapies for cancer, has celebrated the validation of clinical and regulatory pathways for effective therapies leveraging the…

Read MoreFDA Approval Validates MAIA Biotechnology’s Telomere-Targeting Therapy Using a Telomerase Inhibitor

Helix Unveils Clinico-Genomic Datasets Covering Cardiovascular, Metabolic, Immunology, and Inflammation Disorders

Helix, a prominent population genomics company, has introduced new clinico-genomic datasets aimed at empowering life science firms in advancing precision medicine drug discovery and development. These datasets, cultivated through Helix’s…

Read MoreHelix Unveils Clinico-Genomic Datasets Covering Cardiovascular, Metabolic, Immunology, and Inflammation Disorders